Haemonetics (HAE) Reports Q2 Earnings: What Key Metrics Have to Say

For the quarter ended September 2025, Haemonetics (HAE) reported revenue of $327.32 million, down 5.3% over the same period last year. EPS came in at $1.27, compared to $1.12 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $311.07 million, representing a surprise of +5.22%. The company delivered an EPS surprise of +13.39%, with the consensus EPS estimate being $1.12.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Haemonetics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Net revenues- United States: $240.09 million versus $220.36 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -6.2% change.Net revenues- Europe: $42.97 million versus $44.25 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +2.3% change.Net revenues- Japan: $18.01 million compared to the $17.55 million average estimate based on two analysts. The reported number represents a change of +9.7% year over year.Net revenues- Plasma: $125.36 million compared to the $113.89 million average estimate based on three analysts. The reported number represents a change of -9.5% year over year.Net revenues- Hospital: $145.5 million versus the three-analyst average estimate of $147.99 million. The reported number represents a year-over-year change of +5.1%.Net revenues- Blood Center: $56.45 million compared to the $49.04 million average estimate based on three analysts. The reported number represents a change of -17.6% year over year.Operating income- Plasma: $42.59 million versus $60.95 million estimated by two analysts on average.Operating income- Hospital: $29.86 million compared to the $10.86 million average estimate based on two analysts.Operating income- Blood Center: $14.83 million versus $15.51 million estimated by two analysts on average.View all Key Company Metrics for Haemonetics here>>>Shares of Haemonetics have returned -0.5% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks